Chamunda Ele. (CHAMUNDA)

Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 61.60% and profit growth of 334.62% show strong recent momentum.
• P/E of 11.53 and PEG of 0.06 suggest attractive valuation if growth is sustainable.
• ROCE of 30.62% indicates efficient use of capital.
• Piotroski F-Score of 7/9 points to reasonably sound financial fundamentals.
• Promoter holding of 73.55% aligns promoters with minority shareholders.

Concerns

• Missing book value, ROE, and debt-to-equity data makes balance sheet risk difficult to assess.
• Zero dividend means investors depend entirely on future growth and re-rating.
• Profit growth of 334.62% may be a low-base effect and may not be repeatable.
• Small market cap of ₹59 Cr and narrow 52-week range of ₹38-₹53 suggest limited institutional comfort and possible liquidity risk.

AI Analysis

At first glance, Chamunda Ele. looks like a small-cap growth story. A ₹59 Cr market cap with a P/E of 11.53 is not demanding for a company that has grown sales 61.60% and profits 334.62%. But Graham taught me to treat such numbers with suspicion until quality is proven. The latest quarter shows sales of ₹17 Cr and net profit of ₹2 Cr, so the momentum is visible in recent numbers, not just an annual artifact. ROCE of 30.62% is genuinely impressive and suggests the business generates good returns on capital employed. The Piotroski F-Score of 7 out of 9 also points to reasonably sound fundamentals. The PEG ratio of 0.06 screams cheap—if the growth rate is sustainable. I have to pause, though. There is no book value, no ROE, and no debt-to-equity data. Those blanks are a red flag for me; I cannot assess balance sheet safety without knowing equity cushion and leverage. Promoter holding of 73.55% is positive—they are aligned with minority shareholders. But zero dividend means all value creation must come from reinvestment and market re-rating. In a micro-cap with limited data, I would demand a wide margin of safety. The price is within the 52-week range of ₹38 to ₹53, so shares are not at a distressed low. My verdict: this is an interesting fast grower on paper, but I would need more complete financials, cash flow evidence, and several quarters of consistent performance before treating it as a core holding. There is a chance the market is undervaluing genuine growth; there is also a chance the profit spike is a base effect. I will keep it on my watchlist, not my buy list, until the missing data is provided.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer